We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Russia’s sovereign wealth fund announced Wednesday that the country’s Sputnik V COVID-19 vaccine was shown to be 92 percent effective in an interim analysis from global phase 3 trials. Read More
The assay could be used for “accurate evaluation of antibody status before and after infection, in antibody therapies or in vaccination programs,” said EUROIMMUN CEO Wolfgang Schlumberger. Read More
The head of the Butantan Institute, which is leading the trial, does not believe the adverse event is related to the vaccine, Sinovac claims. Read More
Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. Read More
Brazil’s National Agency for Sanitary Surveillance (ANVISA) has suspended Beijing, China-based Sinovac’s phase 3 trial of its COVID-19 vaccine, CoronaVac, halting the study Tuesday to evaluate a serious adverse event that occurred. Read More
Rick Bright, who was leading the vaccine effort at NIH’s Biomedical Advanced Research and Development Authority (BARDA) but was pushed aside by the Trump administration, has joined President-Elect Joe Biden’s Transition COVID-19 Advisory Board. Read More
As Novavax gears up to put its investigational COVID-19 vaccine through a phase 3 U.S. trial this month, the FDA has granted the candidate a Fast-Track designation in order to speed up its regulatory review process. Read More
Pfizer and BioNTech have pulled ahead to become the frontrunners in the race for a COVID-19 vaccine, announcing that the first interim analysis from their late-stage trial showed the candidate was more than 90 percent effective. Read More
The FDA has issued an Emergency Use Authorization (EUA) for Eli Lilly’s monoclonal antibody treatment bamlanivimab (LY-CoV555), clearing the drug for use in high-risk patients with mild-to-moderate COVID-19 who don’t need hospitalization or oxygen. Read More